Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Novartis : Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against Novartis's AFINITOR

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 10:25am CET

Release date- 02102017 - NEW YORK - The U.S. Patent & Trademark Office (PTO) on September 25, 2017 granted Argentum Pharmaceuticals LLC's petition for inter partes review (IPR) against all claims of the last-expiring patent listed as covering Novartis Pharmaceuticals' AFINITOR (everolimus tablet) drug in the Food & Drug Administration's Orange Book.

Argentum challenges claims 13 of Novartis's U.S. Patent No. 9,006,224, which the Orange Book states will expire in 2028. The PTO concluded that Argentum has established a 'reasonable likelihood that [Argentum] would prevail with respect to claims 1-3' of the patent. The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO's Patent Trial & Appeal Board. A final decision on patentability in the IPR is due within 1 year.

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.


Email: http://www.argentumpharmaceuticals.com

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
12/13 Aduro discontinues development of CRS-207
12/12 NOVARTIS : initiates study evaluating impact of higher dosing of Cosentyx in pat..
12/12 NOVARTIS : Sandoz announces new Phase I data showing proposed biosimilar pegfilg..
12/11 NOVARTIS : drug crizanlizumab shown to prolong time to patients' first sickle ce..
12/10 NOVARTIS : Primary analysis results from Novartis pivotal JULIET trial show Kymr..
12/10 NOVARTIS : Primary analysis results from Novartis pivotal JULIET trial show Kymr..
12/09 NOVARTIS : $32,000 Federal Contract Awarded to Alcon Laboratories
12/08DJROCHE : Novartis's Italian Heads Risk Trial for Alleged Market Rigging -Reuters
12/08 ADVANCED ACCELERATOR APPLICATION : s Announces Commencement of Novartis Tender O..
More news
News from SeekingAlpha
12/13 CONATUS : Likely To Dash Ahead Of NASH Data
12/12 Novartis (NVS) Highlights From ASH And SABCS - Slideshow
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
12/11 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 11, 2017
12/11 YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio..
Financials ($)
Sales 2017 49 174 M
EBIT 2017 11 962 M
Net income 2017 7 465 M
Debt 2017 17 812 M
Yield 2017 3,37%
P/E ratio 2017 24,47
P/E ratio 2018 21,32
EV / Sales 2017 4,85x
EV / Sales 2018 4,64x
Capitalization 220 B
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 3,7%
EPS Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS12.01%218 773
JOHNSON & JOHNSON21.53%379 175
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659
AMGEN19.97%128 363